Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
Delayed Nasdaq  -  04:00 2022-06-28 pm EDT
165.03 USD   -3.64%
06/27BeiGene Grants Share Options, Restricted Share Units
MT
06/26Antengene Corporation Limited Announces Clinical Trial Collaboration with BeiGene, Ltd. to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma
CI
06/24Asian ADRs Climb Higher in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Sell: BeiGene

05/09/2022 | 08:49am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about BEIGENE, LTD.
06/27BeiGene Grants Share Options, Restricted Share Units
MT
06/26Antengene Corporation Limited Announces Clinical Trial Collaboration with BeiGene, Ltd...
CI
06/24Asian ADRs Climb Higher in Friday Trading
MT
06/22BEIGENE : Announces Acceptance of Supplemental Biologics License Application in China for ..
PU
06/22INSIDER SELL : Beigene
MT
06/22INSIDER SELL : Beigene
MT
06/22BEIGENE, LTD. : Change in Directors or Principal Officers, Submission of Matters to a Vote..
AQ
06/22Beigene, Ltd. Announces Executive Changes
CI
06/21European ADRs Rise Sharply in Tuesday Trading
MT
06/21SECTOR UPDATE : Health Care Stocks Edge Higher Premarket Tuesday
MT
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2022 1 435 M - -
Net income 2022 -1 349 M - -
Net cash 2022 2 802 M - -
P/E ratio 2022 -11,4x
Yield 2022 -
Capitalization 17 051 M 17 051 M -
EV / Sales 2022 9,93x
EV / Sales 2023 7,28x
Nbr of Employees 8 300
Free-Float 99,0%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 165,03 $
Average target price 303,74 $
Spread / Average Target 84,1%
EPS Revisions
Managers and Directors
John V. Oyler Director
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Lai Wang Global Head-Research & Development
Christiane Langer Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.-34.30%18 382
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.86%44 742
BIONTECH SE-48.01%32 574